TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14732656

Group type: EXPERIMENTAL
Intervention: Verteporfin PDT with 14 mg/m² infusion followed by red light exposure at 60 J/cm²
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Verteporfin PDT with 14 mg/m² infusion followed by red light exposure at 120 J/cm²
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Verteporfin PDT with 14 mg/m² infusion followed by red light exposure at 180 J/cm²
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Verteporfin PDT
Number of subjects: 54
Study: 11558864

Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam 3 g
Number of subjects: 180

Group type: COMPARATOR
Intervention: Ceftriaxone 2 g
Number of subjects: 180
Study: 9491047

Group type: EXPERIMENTAL
Intervention: Teaching (n = 18)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Listening (n = 25)
Number of subjects: 43
Study: 8192130

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 37

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: No medication
Number of subjects: 37
Study: 3316371

Group type: EXPERIMENTAL
Intervention: Ranitidine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 31897548

Group type: EXPERIMENTAL
Intervention: Low-dose (3-7 spheroids/cm2)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Medium-dose (10-30 spheroids/cm2)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High-dose (40-70 spheroids/cm2)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 75
Study: 30132040

Group type: EXPERIMENTAL
Intervention: Haptic guidance (HG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Error amplification (EA)
Number of subjects: 0
Study: 26680374

Group type: EXPERIMENTAL
Intervention: Heme arginate (HA) 3 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 40
Study: 25643127

Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin A injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topiramate
Number of subjects: 0
Study: 23905951

Group type: EXPERIMENTAL
Intervention: Unilateral instrumentation
Number of subjects: 41

Group type: COMPARATOR
Intervention: Bilateral instrumentation
Number of subjects: 41
Study: 20608365

Group type: EXPERIMENTAL
Intervention: Yangjing Decoction at the dose of 400 ml bid for 6 months
Number of subjects: 62

Group type: COMPARATOR
Intervention: Yougui Capsules tid for 6 months
Number of subjects: 62
Study: 18617746

Group type: EXPERIMENTAL
Intervention: Consulting a CAM practitioner
Number of subjects: 42277

Group type: COMPARATOR
Intervention: Daily smoking of cigarettes
Number of subjects: 42277

Group type: EXPERIMENTAL
Intervention: Higher total HADS-T score
Number of subjects: 42277

Group type: EXPERIMENTAL
Intervention: Middle-level education
Number of subjects: 42277
Study: 16854683

Group type: EXPERIMENTAL
Intervention: Mifepristone (10 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 7
Study: 12803593

Group type: EXPERIMENTAL
Intervention: EMLA (n = 53)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Lignocaine 5% ointment (n = 50)
Number of subjects: 103
Study: 10789071

Group type: EXPERIMENTAL
Intervention: Micronized megestrol acetate tablet formulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional megestrol acetate formulation
Number of subjects: 0
Study: 8851417

Group type: EXPERIMENTAL
Intervention: Fast spin-echo sequence with flow compensation, respiratory triggering (RT), and 8 ETL
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Fast spin-echo sequence with 16 ETL
Number of subjects: 5

Group type: COMPARATOR
Intervention: Conventional spin-echo sequences with flow compensation and spatial presaturation
Number of subjects: 5
Study: 1310916

Group type: EXPERIMENTAL
Intervention: Steady-state mild hypothermia (rectal temperature 33.9 +/- 0.7 degrees C)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Steady-state mild hypothermia
Number of subjects: 4

Group type: COMPARATOR
Intervention: Mild hypothermia
Number of subjects: 4

Group type: COMPARATOR
Intervention: Heat exposure (ambient temperature 40 degrees C)
Number of subjects: 4
Study: 6147293

Group type: EXPERIMENTAL
Intervention: Somatostatin at a dose of 250 micrograms/h in saline (n = 12)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 22
Study: 31524081

Group type: EXPERIMENTAL
Intervention: CH2 strain in single infection
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: CH2 strain in mixed infection with EU strain
Number of subjects: 106

Group type: COMPARATOR
Intervention: EU strain
Number of subjects: 106
Study: 30075740

Group type: EXPERIMENTAL
Intervention: Soccer league (n=400)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Soccer league plus vocational training (n=400)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control condition (n=400)
Number of subjects: 1200
Study: 27394978

Group type: EXPERIMENTAL
Intervention: Exenatide (10μg/h for 30min followed by 0.84μg/h for 72h)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 91
Study: 24531238

Group type: EXPERIMENTAL
Intervention: Early rehabilitation interventions including consultation with a rehabilitation physician, pain management, physiotherapy, psychological treatment, and further specialist referrals
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Early rehabilitation interventions
Number of subjects: 76

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 76
Study: 21981661

Group type: EXPERIMENTAL
Intervention: Longer pump time (mean 31.2 ± 7.9 h)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Shorter pump time (mean 22.7 ± 7.3 h)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Longer pump time
Number of subjects: 132
Study: 19225466

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate for 6 months
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Baseline testosterone level in the lowest tertile
Number of subjects: 237
Study: 17462050

Group type: EXPERIMENTAL
Intervention: Integrity-promoting care training programme for staff
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control ward (no intervention)
Number of subjects: 33
Study: 16369194

Group type: EXPERIMENTAL
Intervention: Low-Intensity (LI) exercise training
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-Intensity (HI) exercise training
Number of subjects: 15
Study: 11956118

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 5569

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5569

Group type: EXPERIMENTAL
Intervention: Homocysteine levels
Number of subjects: 5569
Study: 9605718

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study: 7636819

Group type: EXPERIMENTAL
Intervention: EMLA cream (5 minutes application)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lignocaine 1% (injected subcutaneously)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethyl chloride spray
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no local anaesthetic)
Number of subjects: 0
Study: 1968739

Group type: EXPERIMENTAL
Intervention: Xamoterol (0.15 mg/Kg intravenous injection)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Xamoterol during dobutamine infusion
Number of subjects: 16
Study: 655186

Group type: EXPERIMENTAL
Intervention: Acebutolol, 400 to 800 mg daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hydrochlorothiazide, 50 mg daily (with 10 mg of amiloride or 50 mg of spironolactone)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acebutolol, 2000 mg for 48 hours (in-hospital evaluation)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both treatments (acebutolol and diuretics)
Number of subjects: 40
Study: 30801994

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 23735

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 23735

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 23735

Group type: EXPERIMENTAL
Intervention: Risk score model
Number of subjects: 23735
Study: 27789350

Group type: EXPERIMENTAL
Intervention: DMPA 75 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: DMPA 104 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: DMPA 150 mg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 34
Study: 24691155

Group type: EXPERIMENTAL
Intervention: Life-review
Number of subjects: 58

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 58

Group type: COMPARATOR
Intervention: Expressive writing
Number of subjects: 58
Study: 23632801

Group type: EXPERIMENTAL
Intervention: Prolift procedure
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (non-POP patients)
Number of subjects: 67
Study: 21767360

Group type: EXPERIMENTAL
Intervention: Behavioral weight management program with body image module
Number of subjects: 239
Study: 19489898

Group type: EXPERIMENTAL
Intervention: Literacy Express Preschool Curriculum in English‐only (n = 31)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Literacy Express Preschool Curriculum initially in Spanish transitioning to English (n = 31)
Number of subjects: 94

Group type: COMPARATOR
Intervention: High/Scope Curriculum (control n = 32)
Number of subjects: 94
Study: 17724529

Group type: EXPERIMENTAL
Intervention: Pantoprazol 40 mg/day for 12 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 15294061

Group type: EXPERIMENTAL
Intervention: Inhalation with noseclip
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inhalation without noseclip
Number of subjects: 10
Study: 11531216

Group type: EXPERIMENTAL
Intervention: Trophic feedings from day 4 through 14
Number of subjects: 171

Group type: COMPARATOR
Intervention: Standard feedings starting at day 15
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Trophic feedings
Number of subjects: 171

Group type: COMPARATOR
Intervention: Standard feedings
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Bolus feedings
Number of subjects: 171

Group type: COMPARATOR
Intervention: Continuous feedings
Number of subjects: 171
Study: 9760817

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no pentoxifylline)
Number of subjects: 14
Study: 8310978

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg once daily
Number of subjects: 29
Study: 3131884

Group type: EXPERIMENTAL
Intervention: Alfentanil 30 micrograms/kg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fentanyl 5 micrograms/kg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine 2 mg/kg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Lignocaine 10% spray 2 mg/kg to the larynx
Number of subjects: 39
Study: 30910500

Group type: EXPERIMENTAL
Intervention: 1-day educational workshop on patient safety
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study: 28818255

Group type: EXPERIMENTAL
Intervention: Carotid revascularization and intensive medical management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid stenting with embolic protection
Number of subjects: 0

Group type: COMPARATOR
Intervention: No stenting
Number of subjects: 0
Study: 24960435

Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN) with facilitated enrollment into an indigent care discount program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Facilitated enrollment into an indigent care discount program alone (Control)
Number of subjects: 40
Study: 24432037

Group type: EXPERIMENTAL
Intervention: Avanafil (200 mg)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Avanafil (200 mg) 0.5 hours before NTG
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg) 0.5 hours before NTG
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg) 1 hour before NTG
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg) 12 hours before NTG
Number of subjects: 106
Study: 20810219

Group type: EXPERIMENTAL
Intervention: 17β‐estradiol (E)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Progesterone‐plus‐estrogen
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Estrogen therapies unopposed by progesterone
Number of subjects: 53

Group type: COMPARATOR
Intervention: Estrogen‐containing hormone therapy
Number of subjects: 53
Study: 19594262

Group type: EXPERIMENTAL
Intervention: Tailored print-based fruit and vegetable intervention on ethnic identity
Number of subjects: 560

Group type: COMPARATOR
Intervention: Control condition (demographic and social cognitive variables only)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Afrocentric experimental group
Number of subjects: 560

Group type: COMPARATOR
Intervention: Afrocentric control group
Number of subjects: 560
Study: 16708724

Group type: EXPERIMENTAL
Intervention: Ormocer or nanofill composite with flowable liner (Admira Flow or Filtek Flow)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Ormocer or nanofill composite without flowable liner
Number of subjects: 54
Study: 12688320

Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (HDMP) in Group B1
Number of subjects: 194

Group type: COMPARATOR
Intervention: Conventional dose steroids in Group A2 and A3
Number of subjects: 194
Study: 10902981

Group type: EXPERIMENTAL
Intervention: Condensed milk + micronutrients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skimmed milk + micronutrients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Skimmed milk
Number of subjects: 0
Study: 9042991

Group type: EXPERIMENTAL
Intervention: Octreotide, 50 microg, subcutaneous injection 5 min before ingestion of a test meal
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo, subcutaneous injection 5 min before ingestion of a test meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Octreotide with solid meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Octreotide with liquid meal
Number of subjects: 20
Study: 1607272

Group type: EXPERIMENTAL
Intervention: Quinidine bisulphate 500 mg from Teva
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Quinidine bisulphate 250 mg from Teva
Number of subjects: 7

Group type: COMPARATOR
Intervention: Short-acting quinidine sulphate 200 mg
Number of subjects: 7
Study: 3896583

Group type: EXPERIMENTAL
Intervention: Bromhexine (Bisolvon)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 30091064

Group type: EXPERIMENTAL
Intervention: 12-month home exercise program
Number of subjects: 141

Group type: COMPARATOR
Intervention: Equal attention control group
Number of subjects: 141
Study: 27636753

Group type: COMPARATOR
Intervention: Local anti-inflammatory therapy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Surgical intervention on the periodontium in addition to local anti-inflammatory therapy
Number of subjects: 35
Study: 24837707

Group type: EXPERIMENTAL
Intervention: Formal exercise-based cardiac rehabilitation (CR) with exercise prescription based on exercise testing
Number of subjects: 383096

Group type: COMPARATOR
Intervention: Non-formal exercise-based cardiac rehabilitation (CR) without exercise prescription
Number of subjects: 383096

Group type: EXPERIMENTAL
Intervention: Exercise testing sessions
Number of subjects: 383096
Study: 21695708

Group type: EXPERIMENTAL
Intervention: 0.18 W/kg exposure
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1.8 W/kg exposure
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.18 W/kg and 1.8 W/kg exposures
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Other parameters
Number of subjects: 16
Study: 20485708

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 16954654

Group type: EXPERIMENTAL
Intervention: Roflumilast 1,000 microg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 15709892

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Fluoxetine + Cognitive Behavioural Therapy (CBT)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT) alone
Number of subjects: 439

Group type: COMPARATOR
Intervention: No Fluoxetine (placebo)
Number of subjects: 439
Study: 12067044

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (20% energy from fat)
Number of subjects: 13277
Study: 10485771

Group type: EXPERIMENTAL
Intervention: Intramuscular rocuronium (1 mg/kg for infants, 1.8 mg/kg for children)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Intravenous rocuronium (0.45 mg/kg)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Intramuscular rocuronium
Number of subjects: 76
Study: 8938532

Group type: EXPERIMENTAL
Intervention: Ribavirin (1000 or 1200 mg/day for 24 weeks)
Number of subjects: 114
Study: 1936497

Group type: EXPERIMENTAL
Intervention: Mifepristone 600 mg orally
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vacuum aspiration
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 50
Study: 7332739

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ethanol/saline mixture (diluent of PGE2)
Number of subjects: 8
Study: 31292301

Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 4991
Study: 30305146

Group type: EXPERIMENTAL
Intervention: Standardised target effect size
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Standardised observed effect size
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Maximum anticipated effect size
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Maximum observed effect size
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Anticipated target values
Number of subjects: 107
Study: 26962078

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam plus metronidazole
Number of subjects: 1066

Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 1066
Study: 25210879

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of GLP‐1 (0.9 pmol/kg/min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 10
Study: 23234759

Group type: EXPERIMENTAL
Intervention: Supportive site
Number of subjects: 8112

Group type: EXPERIMENTAL
Intervention: Personalized-supportive site
Number of subjects: 8112

Group type: COMPARATOR
Intervention: Information-based site
Number of subjects: 8112

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 8112

Group type: EXPERIMENTAL
Intervention: Supportive conditions
Number of subjects: 8112
Study: 21177352

Group type: EXPERIMENTAL
Intervention: Induction of labour
Number of subjects: 650

Group type: COMPARATOR
Intervention: Expectant monitoring
Number of subjects: 650
Study: 17512607

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine-Fluoxetine Combination (OFC) (6/25, 6/50, or 12/50 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OFC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study: 16306819

Group type: EXPERIMENTAL
Intervention: Single visit (SV group, n = 20)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide for one week (CH group, n = 18)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Leaving the canal empty but sealed for one week (EC group, n = 12)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite irrigation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bacterial growth at the second appointment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide dressing
Number of subjects: 50
Study: 12210784

Group type: EXPERIMENTAL
Intervention: Non-ischemic forearm exercise test
Number of subjects: 19

Group type: COMPARATOR
Intervention: Ischemic forearm exercise test
Number of subjects: 19
Study: 10325560

Group type: EXPERIMENTAL
Intervention: Surgeons' decision
Number of subjects: 344

Group type: COMPARATOR
Intervention: Adjudication process
Number of subjects: 344
Study: 7572707

Group type: EXPERIMENTAL
Intervention: Olive oil diet (40% fat, 22% MUFAs)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sunflower oil diet (40% fat, 22% MUFAs)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sunflower oil diet
Number of subjects: 21

Group type: COMPARATOR
Intervention: NCEP-I diet
Number of subjects: 21
Study: 1673975

Group type: EXPERIMENTAL
Intervention: Cetirizine (15 mg single dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cetirizine (15 mg twice daily for 7 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (single dose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (7 days treatment)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cetirizine (single dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cetirizine (7 days treatment)
Number of subjects: 10
Study: 7284885

Group type: EXPERIMENTAL
Intervention: 12 ml of bupivacaine 0.25 per cent
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 6 ml of bupivacaine 0.5 per cent
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Lateral position maintained after induction
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Turning to the contralateral side after injection of 12 ml bupivacaine 0.25 per cent
Number of subjects: 131
Study: 31570470

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 125

Group type: COMPARATOR
Intervention: Doxorubicin (control)
Number of subjects: 125
Study: 29130655

Group type: EXPERIMENTAL
Intervention: Sacroiliac joint dislocation with anterior plate fixation (Group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Computerized navigation for percutaneous sacroiliac screw (Group B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both interventions (Group A and Group B)
Number of subjects: 50